Best-Performing ETFs of November
Wall Street recorded a subdued November this year. The S&P 500 lost 0.04% over the past month (as of Nov. 28, 2025), the Dow Jones advanced 0.8%, and the Nasdaq Composite was off 0.9%. The ebbing chances of the Fed cutting rates in December weighed on markets in November.Concerns over a potential artificial intelligence (AI) […]
Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple
Quick Read Wells Fargo just raised its price target on Amazon to $295 a share, with an overweight rating. Analysts at Bank of America reiterated a buy rating on Eli Lilly, with a price target of $1,286 from $950. Analysts at Bernstein just reiterated an outperform rating on Apple, noting that its checks show iPhone […]
WHO issues 1st guideline on GLP-1s: 4 updates
In a first, the World Health Organization has issued a guideline on GLP-1s, a drug class that up to 1 in 8 U.S. adults report using, according to KFF research. The WHO’s guideline, published Dec. 1 in JAMA, recommends long-term use of GLP-1 medications be “combined with intensive behavioral therapy.” The guideline included several GLP-1s, […]
WHO Issues First Guidance on Using GLP-1 Drugs to Treat Obesity
By I. Edwards HealthDay ReporterTUESDAY, Dec. 2, 2025 (HealthDay News) — The World Health Organization (WHO) released its first-ever guideline on…
Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice
Glucagon-like peptide-1 receptor (GLP-1R) activation in the brain strongly reduces appetite, but most brain GLP-1Rs are not accessible for systemically administered GLP-1R agonists. Acute activation of nucleus tractus solitarius (NTS) GLP-1 neurons, targeting brain GLP-1Rs, strongly suppresses food intake separate from GLP-1R agonists. However, it is unknown if their chronic stimulation is a viable strategy […]
WHO calls for ‘responsible use’ of GLP-1 drugs for long term obesity care
The guideline reframes obesity as a chronic disease needing lifelong care, recommending GLP-1 therapies with behavioural support rather than relying on medication alone
Will blockbuster obesity drugs revolutionize addiction treatment?
Nature, Published online: 02 December 2025; doi:10.1038/d41586-025-03911-x Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.
Could Weight Loss Drugs Turn Fat Cats Into Svelte Ozempets?
GLP-1 drugs for pets could be the next frontier for the blockbuster weight loss and diabetes drugs.
Doctors call Ozempic a miracle drug. Medicaid officials aren’t so sure.
Breakthroughs in weight-loss medicine are presenting state Medicaid officials with what looks like a sure bet: Spend big now to cover the drugs and reap savings when diabetes, heart disease and cancer rates drop. States are hesitating to take it. The few states that have decided to cover drugs like Ozempic and Wegovy to help […]
Nutrients, Vol. 17, Pages 3778: Consuming Tree Nuts Daily as Between-Meal Snacks Reduces Food Cravings and Improves Diet Quality in American Young Adults at High Metabolic Syndrome Risk
Nutrients, Vol. 17, Pages 3778: Consuming Tree Nuts Daily as Between-Meal Snacks Reduces Food Cravings and Improves Diet Quality in American Young Adults at High Metabolic Syndrome Risk Nutrients doi: 10.3390/nu17233778 Authors: Kate Lillegard Annaliese Widmer John R. Koethe Heidi J. Silver Background: Daily energy intake from snacking behaviors has increased over the past few […]